Welcome to the Striker Lab, Kinase Division!
The Striker Lab is focused on developing new kinase inhibitors that can be used as effective antibiotics. We are particularly interested in using these inhibitors to increase b-lactam susceptibility in bacterial species with both intrinsic and acquired resistance mechanisms. We feel that this new class of antibiotics will be useful as a novel co-therapy in combating antibiotic resistant pathogens.
We believe we can leverage existing knowledge of human kinase inhibitors and our microbiologic expertise to develop these drugs. We have advanced structural and computational tools available and state-of-the-art facilities and research cores at the University of Wisconsin to facilitate these goals. We hope we can spur more interest in kinases as bacterial drug targets through our proof-of-concept research and that we can reveal novel, efficient approaches to drug development.
Overview of the PknB structure with a specific competitive inhibitor. The ligand occupies much of the ATP binding site as well as the back pocket of the kinase.
News and Events
Nate Wlodarchak awarded competitive American Heart Association Fellowship
This fellowship was awarded to study how unique structural changes can inform the development of new clinically relevant kinase inhibitors.
PknB inhibitor paper published in ACS Molecular Pharmecutics
Our paper on inhibition of PknB by aminofurazans and microbiological potentiation with b-lactams was published in October!
Dan Turner Joins Lab!
Dan is a new graduate student in the MCP training program and he did his undergraduate studies at UW-Madison. He will be working on differences in the behavior of HIV in male and female cell lines.